KöhlerG, MilsteinC: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975; 256:495–497.
2.
CarterP: Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer, 2001; 1:118–129.
3.
BeckA, WurchT, CorvaiaN: Therapeutic antibodies and derivatives: From the bench to the clinic. Curr Pharm Biotechnol, 2008; 9:421–422.
4.
NelsonAL, DhimoleaE, ReichertJM: Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov, 2010; 9:767–774.
5.
VultaggioA, MaggiE, MatucciA: Immediate adverse reactions to biologicals: From pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol, 2011; 11:262–268.
6.
KlasterskyJ: Adverse effects of the humanized antibodies used as cancer therapeutics. Curr Op Oncol, 2006; 18:316–320.
7.
MyskowskiPL, HalpernAC: Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer. Curr Allergy Asthma Rep, 2008; 8:63–68.
8.
SvobodaM, PoprachA, DobesS, KissI, VyzulaR: Cardiac toxicity of targeted therapies used in the treatment for solid tumours: A review. Cardiovasc Toxicol, 2012; 12:191–207.
9.
BaasJM, KrensLL, GuchelaarHJ, et al.: Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review. Cancer Treat Rev, 2012; 38:505–514.
10.
Micromedex® Healthcare Series. Greenwood Village, CO: Thomson Reuters (Healthcare).
